Compare LGVN & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | BRFH |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 38.7M |
| IPO Year | 2021 | 2010 |
| Metric | LGVN | BRFH |
|---|---|---|
| Price | $0.80 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 379.1K | 7.8K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | 10.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | $211,467.00 |
| Revenue This Year | N/A | $115.22 |
| Revenue Next Year | $10.81 | $16.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 92.09 |
| 52 Week Low | $0.48 | $2.25 |
| 52 Week High | $1.80 | $6.08 |
| Indicator | LGVN | BRFH |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 42.99 |
| Support Level | $0.74 | $2.26 |
| Resistance Level | $0.86 | $2.53 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 78.25 | 27.36 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.